A clinicopathological study of human liver allograft recipients harboring preformed IgG lymphocytotoxic antibodies.

PubWeight™: 1.50‹?› | Rank: Top 4%

🔗 View Article (PMC 2956418)

Published in Hepatology on September 01, 1992

Authors

A J Demetris1, K Nakamura, A Yagihashi, Y Iwaki, S Takaya, G G Hartman, N Murase, O Bronsther, R Manez, J J Fung

Author Affiliations

1: Department of Pathology, University of Pittsburgh Health Sciences Center, PA 15213.

Articles citing this

The significance of donor-specific HLA antibodies in rejection and ductopenia development in ABO compatible liver transplantation. Am J Transplant (2011) 1.98

Successful hamster-to-rat liver xenotransplantation under FK506 immunosuppression induces unresponsiveness to hamster heart and skin. Transplantation (1993) 1.94

The biological basis of and strategies for clinical xenotransplantation. Immunol Rev (1994) 1.56

Preformed lymphocytotoxic antibodies: the effects of class, titer and specificity on liver vs. heart allografts. Hepatology (1992) 1.18

Liver allograft rejection in sensitized recipients. Observations in a clinically relevant small animal model. Am J Pathol (1993) 1.05

The role of donor-specific HLA alloantibodies in liver transplantation. Am J Transplant (2014) 0.96

Assessing risk in liver transplantation. Special reference to the significance of a positive cytotoxic crossmatch. Ann Surg (1996) 0.95

Antibody-mediated rejection as a contributor to previously unexplained early liver allograft loss. Liver Transpl (2014) 0.85

Combined liver-kidney transplantation and the effect of preformed lymphocytotoxic antibodies. Transpl Immunol (1994) 0.85

Role of splenectomy in human liver transplantation under modern-day immunosuppression. Dig Dis Sci (1998) 0.84

Immunoglobulin G lymphocytotoxic antibodies in clinical liver transplantation: studies toward further defining their significance. Hepatology (1995) 0.83

The impact of positive T-cell lymphocytotoxic crossmatch on intestinal allograft rejection and survival. Transplant Proc (2000) 0.82

The liver allograft, chronic (ductopenic) rejection, and microchimerism: what can they teach us? Transplant Proc (1995) 0.82

The Future of Xenotransplantation. Ann Surg (1992) 0.80

Reduction of primary nonfunction with prostaglandin E1 after clinical liver transplantation. Transplant Proc (1995) 0.80

Acute liver allograft antibody-mediated rejection: an inter-institutional study of significant histopathological features. Liver Transpl (2014) 0.78

ABO-compatible liver allograft antibody-mediated rejection: an update. Curr Opin Organ Transplant (2015) 0.78

Increased bile duct complications and/or chronic rejection in crossmatch positive human liver allografts. Transplant Proc (1999) 0.76

Clinical significance of donor-specific human leukocyte antigen antibodies in liver transplantation. World J Gastroenterol (2015) 0.76

Preformed antibodies in sensitized recipients: effect of immunoglobulin titer, class, and specificity on liver and heart allografts. Transplant Proc (1993) 0.75

Aspects of liver transplant pathology with emphasis on rejection and its mechanisms. J Clin Pathol (1994) 0.75

Preoperative selective desensitization of live donor liver transplant recipients considering the degree of T lymphocyte cross-match titer, model for end-stage liver disease score, and graft liver volume. J Korean Med Sci (2014) 0.75

Articles cited by this

Fifteen years of clinical liver transplantation. Gastroenterology (1979) 7.19

Hyperacute rejection of kidney allografts, associated with pre-existing humoral antibodies against donor cells. Lancet (1966) 5.54

Progress in and deterrents to orthotopic liver transplantation, with special reference to survival, resistance to hyperacute rejection, and biliary duct reconstruction. Transplant Proc (1974) 5.53

Liver, kidney, and thoracic organ transplantation under FK 506. Ann Surg (1990) 5.01

Shwartzman reaction after human renal homotransplantation. N Engl J Med (1968) 4.05

"Hyperacute" renal-homograft rejection in man. N Engl J Med (1968) 3.37

Pathology of hepatic transplantation: A review of 62 adult allograft recipients immunosuppressed with a cyclosporine/steroid regimen. Am J Pathol (1985) 3.16

Mechanism and modification of rejection of heterografts between divergent species. Transplant Proc (1970) 2.63

A review of adult and pediatric post-transplant liver pathology. Pathol Annu (1987) 2.62

Liver transplantation across ABO blood groups. Surgery (1986) 2.39

Humoral antibodies and coagulation mechanisms in the accelerated or hyperacute rejection of renal homografts in sensitized canine recipients. Surgery (1970) 2.38

Orthotopic liver transplantation: a pathological study of 63 serial liver biopsies from 17 patients with special reference to the diagnostic features and natural history of rejection. Hepatology (1985) 2.18

Liver transplantation against T cell-positive warm crossmatches. Transplant Proc (1984) 1.96

The adverse impact on liver transplantation of using positive cytotoxic crossmatch donors. Transplantation (1992) 1.83

Positive crossmatch in primary human liver allografts under cyclosporine or FK 506 therapy. Transplant Proc (1991) 1.77

Evidence for hyperacute rejection of human liver grafts: The case of the canary kidneys. Clin Transplant (1989) 1.74

Liver transplantation in positive cytotoxic crossmatch cases using FK506, high-dose steroids, and prostaglandin E1. Transplantation (1992) 1.68

Evidence for an immune response to HLA class I antigens in the vanishing-bileduct syndrome after liver transplantation. Lancet (1987) 1.68

Antibody-mediated rejection of human orthotopic liver allografts. A study of liver transplantation across ABO blood group barriers. Am J Pathol (1988) 1.45

Evaluation of protocol before transplantation and after reperfusion biopsies from human orthotopic liver allografts: considerations of preservation and early immunological injury. Hepatology (1990) 1.38

Evaluation of dithiothreitol (DTT) for inactivation of IgM antibodies. J Clin Pathol (1978) 1.33

Hepatic transplantation into sensitized recipients. Demonstration of hyperacute rejection. Transplantation (1987) 1.31

Signs of hyperacute rejection of liver grafts in rhesus monkeys after donor-specific presensitization. Transplant Proc (1987) 1.30

Liver transplantation across ABO blood group barriers. Lancet (1990) 1.29

Hyperacute renal allograft rejection in the rabbit. The role of platelet-activating factor and of cationic proteins derived from polymorphonuclear leukocytes and from platelets. Lab Invest (1984) 1.24

THE INCIDENCE, CAUSE, AND SIGNIFICANCE OF IMMEDIATE AND DELAYED OLIGURIA OR ANURIA AFTER HUMAN RENAL TRANSPLANTATION. Surg Gynecol Obstet (1964) 1.18

The definition of ABO factors in transplantation: relation to other humoral antibody states. Transplant Proc (1987) 1.13

Influence of positive lymphocyte crossmatch and HLA mismatching on vanishing bile duct syndrome in human liver allografts. Transplantation (1988) 1.10

The vascular endothelial cell antigen system. Transplantation (1985) 1.09

A primate model of hyperacute renal allograft rejection. Am J Pathol (1975) 1.09

The nature of experimental second-set kidney transplant rejection. 2. The mimicking of the haemodynamic upset by pharmacological and other means. Br J Exp Pathol (1971) 1.08

Hyperacute rejection in liver transplantation: a case report. Transplant Proc (1989) 1.07

Histopathology of serial graft biopsies from liver transplant recipients. Am J Pathol (1984) 1.03

Hyperacute renal allograft rejection in the rabbit. Vasoconstriction demonstrated by microangiography. Transplantation (1983) 1.03

Interactions between liver allografts and lymphocytotoxic alloantibodies in inbred rats. Hepatology (1986) 0.99

Intraoperative blood transfusions in highly alloimmunized patients undergoing orthotopic liver transplantation. Transplantation (1989) 0.98

Relationship between the liver and lymphocytotoxic alloantibodies in inbred rats. Specific absorption by nonparenchymal liver cells. Transplantation (1988) 0.93

Articles by these authors

Cell migration, chimerism, and graft acceptance. Lancet (1992) 12.24

Cell migration and chimerism after whole-organ transplantation: the basis of graft acceptance. Hepatology (1993) 8.76

Bone marrow as a potential source of hepatic oval cells. Science (1999) 8.52

The outer membrane proteins of Gram-negative bacteria: biosynthesis, assembly, and functions. Annu Rev Biochem (1978) 7.96

Urban residential environments and senior citizens' longevity in megacity areas: the importance of walkable green spaces. J Epidemiol Community Health (2002) 7.79

Kidney transplantation under FK 506. JAMA (1990) 7.45

The use of cyclosporin A and prednisone in cadaver kidney transplantation. Surg Gynecol Obstet (1980) 7.40

The many faces of multivisceral transplantation. Surg Gynecol Obstet (1991) 6.89

Microdroplet testing for HLA-A, -B, -C, and -D antigens. The Phillip Levine Award Lecture. Am J Clin Pathol (1978) 6.88

T-cell-mediated regulation of osteoclastogenesis by signalling cross-talk between RANKL and IFN-gamma. Nature (2000) 6.49

Long survival in rats after multivisceral versus isolated small-bowel allotransplantation under FK 506. Surgery (1991) 5.92

Effects of heating in dodecyl sulfate solution on the conformation and electrophoretic mobility of isolated major outer membrane proteins from Escherichia coli K-12. J Biochem (1976) 5.52

Liver, kidney, and thoracic organ transplantation under FK 506. Ann Surg (1990) 5.01

Intestinal transplantation in composite visceral grafts or alone. Ann Surg (1992) 4.96

Murine liver allograft transplantation: tolerance and donor cell chimerism. Hepatology (1994) 4.32

DNA sequence of the gene for the outer membrane lipoprotein of E. coli: an extremely AT-rich promoter. Cell (1979) 4.31

Donor cell chimerism permitted by immunosuppressive drugs: a new view of organ transplantation. Immunol Today (1993) 4.29

Pancreatic islet transplantation after upper abdominal exenteration and liver replacement. Lancet (1990) 4.18

Liver transplantation in the United States, 1999-2008. Am J Transplant (2010) 3.92

Replacement of donor lymphoid tissue in small-bowel transplants. Lancet (1991) 3.85

Elucidation of the Erwinia uredovora carotenoid biosynthetic pathway by functional analysis of gene products expressed in Escherichia coli. J Bacteriol (1990) 3.78

Adeno-associated virus vectors can be efficiently produced without helper virus. Gene Ther (1998) 3.77

Massive outbreak of Escherichia coli O157:H7 infection in schoolchildren in Sakai City, Japan, associated with consumption of white radish sprouts. Am J Epidemiol (1999) 3.75

The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J Biol Chem (1994) 3.75

Severe osteopetrosis, defective interleukin-1 signalling and lymph node organogenesis in TRAF6-deficient mice. Genes Cells (1999) 3.69

Hepatic artery embolization in 120 patients with unresectable hepatoma. Radiology (1983) 3.67

Systemic chimerism in human female recipients of male livers. Lancet (1992) 3.63

Variable chimerism, graft-versus-host disease, and tolerance after different kinds of cell and whole organ transplantation from Lewis to brown Norway rats. Transplantation (1995) 3.63

Role of positive charge on the amino-terminal region of the signal peptide in protein secretion across the membrane. Proc Natl Acad Sci U S A (1982) 3.44

Selected topics on FK 506, with special references to rescue of extrahepatic whole organ grafts, transplantation of "forbidden organs," side effects, mechanisms, and practical pharmacokinetics. Transplant Proc (1991) 3.40

Cardiovascular anomaly, impaired actin bundling and resistance to Src-induced transformation in mice lacking p130Cas. Nat Genet (1998) 3.38

Chimerism after liver transplantation for type IV glycogen storage disease and type 1 Gaucher's disease. N Engl J Med (1993) 3.36

Parallel neural networks for learning sequential procedures. Trends Neurosci (1999) 3.35

Orthotopic liver transplantation for patients with hepatitis B virus-related liver disease. Hepatology (1991) 3.34

Kidney transplantation under FK 506 immunosuppression. Transplant Proc (1991) 3.31

Early trials with FK 506 as primary treatment in liver transplantation. Transplant Proc (1990) 3.29

Use of OKT3 with cyclosporin and steroids for reversal of acute kidney and liver allograft rejection. Nephron (1987) 3.26

Rejection of multivisceral allografts in rats: a sequential analysis with comparison to isolated orthotopic small-bowel and liver grafts. Surgery (1990) 3.18

Redox regulation of cellular activation. Annu Rev Immunol (1997) 3.17

Calreticulin: one protein, one gene, many functions. Biochem J (1999) 3.16

The effect of graft function on FK506 plasma levels, dosages, and renal function, with particular reference to the liver. Transplantation (1991) 3.14

Natural history of branch duct intraductal papillary-mucinous neoplasms of the pancreas without mural nodules: long-term follow-up results. Gut (2007) 3.11

Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. Mol Pharmacol (1994) 3.05

Different sensitivity to wortmannin of two vacuolar sorting signals indicates the presence of distinct sorting machineries in tobacco cells. J Cell Biol (1995) 2.93

Long-term survival after liver transplantation in 4,000 consecutive patients at a single center. Ann Surg (2000) 2.91

Calreticulin is essential for cardiac development. J Cell Biol (1999) 2.88

Functional characterization of infiltrating T lymphocytes in human hepatic allografts. Hum Immunol (1986) 2.84

The lost chord: microchimerism and allograft survival. Immunol Today (1996) 2.81

Hematolymphoid cell trafficking, microchimerism, and GVH reactions after liver, bone marrow, and heart transplantation. Transplant Proc (1993) 2.81

Successful liver transplantation from crossmatch-positive donors. Transplant Proc (1981) 2.80

Synergistic release of Ca2+ from IP3-sensitive stores evoked by synaptic activation of mGluRs paired with backpropagating action potentials. Neuron (1999) 2.79

Metastatic patterns of prostatic cancer. Correlation between sites and number of organs involved. Cancer (1984) 2.78

Experimental investigation of geologically produced antineutrinos with KamLAND. Nature (2005) 2.75

Cadaveric small bowel and small bowel-liver transplantation in humans. Transplantation (1992) 2.75

THE IMMUNOSUPPRESSIVE EFFECTS OF FR 900506 IN RATS RECEIVING HETEROTOPIC CARDIAC ALLOGRAFTS. Surg Res Commun (1987) 2.75

Loss of teratogenic response to 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) in mice lacking the Ah (dioxin) receptor. Genes Cells (1997) 2.72

Interethnic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian populations. Clin Pharmacol Ther (1985) 2.69

Construction of versatile expression cloning vehicles using the lipoprotein gene of Escherichia coli. EMBO J (1982) 2.68

Treatment of cyclosporin-induced haemolytic uraemic syndrome with FK506. Lancet (1990) 2.66

Distribution of the insertion sequence IS1 in gram-negative bacteria. Nature (1981) 2.63

Management of intestinal transplantation in humans. Transplant Proc (1992) 2.62

Mitochondrial DNA damage and dysfunction associated with oxidative stress in failing hearts after myocardial infarction. Circ Res (2001) 2.62

Involvement of receptor activator of nuclear factor kappaB ligand/osteoclast differentiation factor in osteoclastogenesis from synoviocytes in rheumatoid arthritis. Arthritis Rheum (2000) 2.61

Rac1 is required for the formation of three germ layers during gastrulation. Oncogene (1998) 2.61

Effect of hepatic dysfunction and T tube clamping on FK 506 pharmacokinetics and trough concentrations. Transplant Proc (1990) 2.60

Suppression of allograft rejection with FK506. I. Prolonged cardiac and liver survival in rats following short-course therapy. Transplantation (1990) 2.59

Incidence and treatment of rejection episodes in primary orthotopic liver transplantation under FK 506. Transplant Proc (1991) 2.59

Cardiac fibrosis in mice lacking brain natriuretic peptide. Proc Natl Acad Sci U S A (2000) 2.58

The prediction of risk of recurrence and time to recurrence of hepatocellular carcinoma after orthotopic liver transplantation: a pilot study. Hepatology (1997) 2.57

K-ras is essential for the development of the mouse embryo. Oncogene (1997) 2.57

Messenger ribonucleic acid of the lipoprotein of the Escherichia coli outer membrane. II. The complete nucleotide sequence. J Biol Chem (1980) 2.57

FK506 "rescue" for resistant rejection of renal allografts under primary cyclosporine immunosuppression. Transplantation (1994) 2.50

Pregnancy after liver transplantation under tacrolimus. Transplantation (1997) 2.50

A randomized trial of primary liver transplantation under immunosuppression with FK 506 vs cyclosporine. Transplant Proc (1991) 2.49

Pharmacokinetics of FK 506: preclinical and clinical studies. Transplant Proc (1990) 2.48

Propeptide of a precursor to a plant vacuolar protein required for vacuolar targeting. Proc Natl Acad Sci U S A (1991) 2.48

Carcinoma of the stomach in incipient phase: its histogenesis and histological appearances. Gan (1968) 2.44

Regulatory region of the gene for the ompA protein, a major outer membrane protein of Escherichia coli. Proc Natl Acad Sci U S A (1980) 2.44

Murine homolog of SALL1 is essential for ureteric bud invasion in kidney development. Development (2001) 2.42

Prioritization and organ distribution for liver transplantation. JAMA (1994) 2.38

Isolation of recombinant adeno-associated virus vector-cellular DNA junctions from mouse liver. J Virol (1999) 2.37

Toxicology of FK-506 in the Lewis rat. Transplant Proc (1987) 2.37

Osteoarthritis development in novel experimental mouse models induced by knee joint instability. Osteoarthritis Cartilage (2005) 2.36

Fluorescence in situ hybridization using 16S rRNA-targeted oligonucleotides reveals localization of methanogens and selected uncultured bacteria in mesophilic and thermophilic sludge granules. Appl Environ Microbiol (1999) 2.33

The human amygdala plays an important role in gaze monitoring. A PET study. Brain (1999) 2.33

Thoracic duct drainage before and after cadaveric kidney transplantation. Surg Gynecol Obstet (1979) 2.33

The antibody crossmatch in liver transplantation. Surgery (1986) 2.33

The incidence, timing, and management of biliary tract complications after orthotopic liver transplantation. Ann Surg (1994) 2.32